Moberg Pharma AB has entered into an agreement with Randob Labs to divest the brand Balmex® for a total consideration of $4.25 million (34.6 million SEK) plus the inventory value at closing.
The divestment is expected to result in a capital gain of circa $0.5 million (4.4 million SEK), enabling Moberg Pharma to further focus resources on its larger brands.
The transaction is expected to close in April.
“We are pleased with the divestment. We have now successfully divested most of our minor brands, enabling us to focus our resources on growing our larger brands”, says Peter Wolpert, CEO Moberg Pharma.